COMMUNIQUÉS West-GlobeNewswire

Tiny Health Named No. 208 on the 2026 Inc. 5000 List of America’s Fastest-Growing Private Companies
13/08/2026
Microbiome Innovator Recognized for 1,624% Three-Year Revenue Growth, Earning a Place Among the Nation’s Most Successful Independent Businesses AUSTIN, Texas, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Tiny Health , the [...]
WellBridge Surgical Named No. 988 on the 2026 Inc. 5000 List, the Most Prestigious Ranking of America’s Fastest-Growing Private Companies
13/08/2026
Following Significant Revenue Growth Over the Past Three Years, Earning a Place Among the Nation’s Most Successful Independent Businesses INDIANAPOLIS, Aug. 13, 2026 (GLOBE NEWSWIRE) -- WellBridge Surgical today [...]
Rapport Semestriel 2026 Valneva
13/08/2026
Rapport Semestriel 2026 Valneva Pièce jointe Financial Report HY1 2026 (FR) (2026-08-12) (002)
Valneva Half-Year 2026 Financial Report
13/08/2026
Valneva Half-Year 2026 Financial Report Attachment Financial Report HY1 2026 (EN) (2026-08-12) (002)
Aligned Marketplace Raises $20 Million, Achieves Measurable Outcomes with Large Employers
13/08/2026
A Third-Party Validated 12 Percent Reduction in Total Cost of Care Delivered in Year One For A Large Fortune 500 Company Proves the Independent Primary Care Model Works at Scale NEW YORK, Aug. 13, 2026 (GLOBE NEWSWIRE [...]
City of Mobile proclaims Project Persevere Day as The Helios Alliance Reports 117,444 Services Delivered in First Year of Opioid Abatement Program
13/08/2026
Sixteen organizations delivered 117,444 services at $143.81 per person — among the most efficient deployments of opioid settlement funds nationally — as a public awareness campaign prepares to launch Mobile, ALABAMA, [...]
Sanofi: Informations relatives au nombre de droits de vote et d'actions - Juillet 2026
13/08/2026
Informations relatives au nombre total de droits de vote et d’actions prévues par l’article L. 233-8 II du Code de commerce et l’article 223-16 du Règlement général de l’Autorité des Marchés Financiers Sanofi Société [...]
Sanofi: Information concerning the total number of voting rights and shares - July 2026
13/08/2026
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’ [...]
Pelthos Therapeutics Announces Second Quarter 2026 Financial Results
13/08/2026
Zelsuvmi ® net product revenue grew 45% to $15.4 million during the second quarter of 2026 from $10.7 million in the first quarter of 2026 11,925 Zelsuvmi units were dispensed by 4,571 unique prescribers during the [...]
Cellectar Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates
13/08/2026
Site Activation Initiated for Confirmatory Phase 3 Study of Iopofosine I 131 with New Drug Application Submission Planned for mid-2027 under the FDA’s Accelerated Approval Program Presented Data from CLOVER WaM Trial of [...]
Liminatus Pharma Announces Transfer to Nasdaq Capital Market and Extension to Regain Compliance with Minimum Bid Price Requirement
13/08/2026
FULLERTON, Calif., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (Nasdaq: LIMN) (“Liminatus” or the “Company”), a biopharmaceutical company developing novel therapies for cancer and other serious diseases, [...]
MediPharm Labs Reports Positive Q2 2026 Net Income and Second Consecutive Quarter of Positive Adjusted EBITDA
13/08/2026
Q2 2026 Adjusted EBITDA 1 of $0.9M, the Company’s strongest quarterly performance since 2019 2 Positive net income in Q2 2026, compared with a net loss of $3.8M in Q2 2025 OPEX decreased 44% in Q2 2026 versus Q2 2025 [...]
Ascendis Pharma Reports Second Quarter 2026 Financial Results
13/08/2026
– Q2 2026 product revenue of €315 million (+105% Y/Y), comprising €252 million for YORVIPATH ® , €55 million for SKYTROFA ® , and €8 million for YUVIWEL ® – Through July 31, more than 220 unique YUVIWEL patient [...]
Cormedix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
13/08/2026
‒ Q2 2026 Consolidated Revenue of $101.9 million ‒ ‒ Q2 2026 Net Income of $26.0 million ; Adjusted EBITDA of $58.7 million ‒ ‒ Company Maintains FY 2026 Revenue and Raises Adjusted EBITDA Guidance ‒ ‒ Conference Call [...]
NervGen Reports Second Quarter 2026 Financial Results and Provides Business Updates
13/08/2026
Site activation and screening for the Phase 3 RESTORE study is expected to begin in September 2026, with the first participant anticipated to be dosed shortly thereafter. Strengthened leadership team, appointing Keith [...]
Collegium Announces $50 Million Accelerated Share Repurchase Program
13/08/2026
STOUGHTON, Mass., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading biopharmaceutical company focused on improving the lives of people living with serious and often misunderstood [...]
Abeona Therapeutics® Reports Second Quarter 2026 Results and Provides Business Update
13/08/2026
- Q2 net ZEVASKYN® revenue increased 31% quarter-over-quarter to $11.4 million – - Five patients treated with ZEVASKYN in Q2 2026 and three treatments in Q3 2026 to-date; since launch, 12 treatments completed – - [...]
Cabaletta Bio Reports Second Quarter 2026 Financial Results and Provides Business Update
13/08/2026
Registrational RESET-Myositis ® clinical data on track to be reported in mid-2027 to support 2H27 BLA submission for rese-cel Juvenile myositis Phase 1/2 data expected to be submitted with BLA to support potential FDA [...]
MiNK Therapeutics Reports Second Quarter 2026 Financial Results and Reports Observations from Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury
13/08/2026
First patients treated in randomized Phase 2 trial C-1300-02 were alive at Day 28, with improved oxygenation, resolution of ARDS with return to spontaneous breathing and liberation from vasopressor support Clinical [...]

Pages